Previous 10 | Next 10 |
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its first quarter 2023 financial results on Thursday, May 11, 2023, following the close of the U.S. financial markets. Amylyx’ senior management team will host a conference call ...
2023-05-02 11:37:13 ET Biogen has set a price for its recently approved ALS therapy Qalsody (tofersen) at $14,230 per dose. Given that 14 doses are required in the first year of treatment, that comes out to just under $200K for the first year alone, Endpoints News reported...
Ms. Nakamura brings over 30 years of leadership in commercializing therapies internationally, including most recently as SVP, Head of Asia at Alnylam Pharmaceuticals Joins Amylyx as a key leader with the goal of bringing AMX0035 to as many people who may benefit around the world as possib...
- Recently published preclinical data demonstrate initial proof-of-concept for the therapeutic development of AMX0035 (sodium phenylbutyrate and taurursodiol) in Wolfram syndrome Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the 22 nd Annual Needham Virtual Healthcare Conference. The conference is being conducted in a virtual ...
2023-04-10 17:30:11 ET Gainers: Nogin ( NOGN ) +18% . Allakos ( ALLK ) +5% . TPI Composites ( TPIC ) +5% . SMART Global Holdings ( SGH ) +3% . PriceSmart ( PSMT ) +3% . Losers: NVIDIA ( NVDA ) -26% . Kur...
2023-04-03 05:21:52 ET Goldman Sachs is sticking with its S&P 500 ( SP500 ) ( NYSEARCA: SPY ) target of little change by year end as valuations and earnings face headwinds near term, its equity team said. "Our Long Duration basket has outperformed the Short Duration bask...
2023-03-31 10:20:59 ET Mizuho has initiated Amylyx Pharmaceuticals ( NASDAQ: AMLX ) with a buy rating saying the firm's conversations with key opinion leaders indicate uptake of the company's ALS therapy Relyvrio is high among doctors and payors. The firm has a $52 price t...
2023-03-28 08:03:39 ET Summary Amylyx's Relyvrio, a novel combination of sodium phenylbutyrate and taurursodiol, offers potential functional and survival benefits for ALS patients. The drug has gained approval in the US and Canada, with efforts to secure approval in Europe underwa...
2023-03-14 10:08:44 ET Gainers: PaxMedica ( PXMD ) +36% . Avid Bioservices ( CDMO ) +25% . Amylyx Pharmaceuticals ( AMLX ) +17% . Euda Health ( EUDA ) +17% . Addex Therapeutics ( ADXN ) +11% . Losers: Rapt Therap...
News, Short Squeeze, Breakout and More Instantly...
Amylyx Pharmaceuticals Inc. Company Name:
AMLX Stock Symbol:
NASDAQ Market:
Amylyx Pharmaceuticals Inc. Website:
- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Am...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx’ management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss the acquisition of avexitide from Eiger ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The conference is being conducted in-person in Miam...